Supplemental Oxygen in Pulmonary Fibrosis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis|
- Change in dyspnea from immediately prior to one month after starting daily-use supplemental oxygen [ Time Frame: One month post daily-use supplemental oxygen implementation ]
- Change in quality of life, fatigue and cough from prior to one month after daily-use supplemental oxygen implementation [ Time Frame: One month after daily-use supplemental oxygen implementation ]
- Change in day-to-day functioning and activity space from prior to one month after daily-use supplemental oxygen implementation [ Time Frame: One month after daily-use supplemental oxygen implementation ]Functioning will be captured by having patients wear an activity monitor, and activity space will be capture by having patients wear a mobile GPS recorder.
|Study Start Date:||October 2013|
|Estimated Study Completion Date:||September 2016|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Pulmonary fibrosis patients
Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
Primary supporter/caregiver of patient with pulmonary fibrosis
We will interview primary supporters/caregivers of people living with PF to learn from a different perspective of what it's like to use supplemental oxygen, both for the person living with PF and the primary supporter him/herself.
Prescribers of supplemental oxygen
We will interview supplemental oxygen prescribers to better understand their practices around prescribing oxygen and their expectations for the patients to whom they prescribe supplemental oxygen.
The investigators aim to recruit patients with PF to participate in interviews and/or a one-year study of supplemental oxygen (O2). In the one-year study, the investigators will collect data before and for one year after PF patients are prescribed daily-use supplemental oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough, and day-to-day functioning before and after O2.
In addition to this, the investigators will interview O2 prescribers and primary supporters/caregivers of PF patients prescribed daily-use O2 to understand the perceptions of others affected by supplemental O2.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01961362
|Contact: Amanda Belkin, MPH||855-609-0010||support@PFresearch.org|
|United States, Colorado|
|National Jewish Health Interstitial Lung Disease Program||Recruiting|
|Denver, Colorado, United States, 80206|
|Contact: Amanda Belkin, MPH|
|Principal Investigator:||Jeff Swigris, DO, MS||National Jewish Health|